|
|
|
| Effects of Maintenance Hemodialysis Combined with Hemoperfusion on Toxin Clearance and Neuroendocrine Hormone in Uremic Patients with Hypertension |
| WANG Ting, LI Yufang, ZHANG Li, et al |
| The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Urumqi 830054, China |
|
|
|
|
Abstract Objective: To analyze the effects of maintenance hemodialysis (MHD) combined with hemoperfusion (HP) on toxin clearance and neuroendocrine hormones in patients with uremia and hypertension. Methods: A total of 92 uremic patients with hypertension who were admitted to our hospital from June 2018 to June 2020 were selected and divided into the control group (MHD group, n=46) and the observation group (HP+MHD group, n=46) by random table method. Clinical data of patients were collected to compare the changes in the levels of toxin level factors C-reactive protein (CRP), homocysteine (Hcy), macronutrient toxin (β2-MG), horse uric acid (HA), parathyroid hormone (PTH) levels, changes in the levels of neuroendocrine hormones angiotensin Ⅱ (Ang Ⅱ), renin (PRA), aldosterone (Ald), and the occurrence of adverse reactions in both groups before and after treatment. Results: After treatment, the levels of CRP, Hcy, β2-MG, HA and PTH in patients of the observation group decreased compared with those before treatment, while the levels of β2-MG in patients of the control group decreased, but the levels of CRP, Hcy, HA and PTH increased compared with those before treatment, and the levels of endotoxin in the observation group after treatment were compared with those in the control group (P<0. 05), the improvement effect of neuroendocrine hormones Ang Ⅱ, PRA and Ald in the observation group patients after treatment was significantly different compared with the control group (P<0. 05), and the adverse reactions in the observation group patients were significantly lower than those in the control group (P<0. 05). Conclusion: Maintenance hemodialysis combined with hemoperfusion in the treatment of uremic patients with hypertension can effectively remove toxins from the patient's body and reduce the secretion of neuroendocrine hormones, and the clinical effect is significant.
|
|
|
|
|
|
[1] 伍梦寒,徐艺文,艾霜兰,等.尿毒症患者血液透析所致导管相关性血流感染的细菌培养和药敏分析[J].中国医学装备,2020,17(4):110-113.
[2] Aghli V,Valizadeh H,Habibzadeh S,et al.The effect of organizational factors on creativity in the iranian academic center for education,culture & research uremia branch[J].ACADEMICIA An International Multidisciplinary Research Journal,2021,11(2):1436-1454.
[3] Nimrit,Goraya,Donald E,Wesson.Novel dietary and pharmacologic approaches for acid-base modulation to preserve kidney function and manage uremia[J].Current opinion in nephrology and hypertension,2020,29(1):39-48
[4] 袁 茜,谢 攀,李绍华,等.尿毒症患者肠道菌群与外周血辅助性T细胞17/调节性T细胞失衡的关系[J].中国临床医生杂志,2021,49(10):1192-1196.
[5] 熊小荣,黄玉麟,李彦黎.多种透析方法联合应用于尿毒症的治疗观察及对患者PTH、25-羟基维生素D水平的影响[J].临床和实验医学杂志,2021,20(14):1517-1521.
[6] 中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.
[7] 香美,倪兆慧,刘玉宁,等.慢性肾衰竭中西医结合诊疗指南[J].河北中医,2016,38(2):313-317.
[8] D Fliser,J Hoyer.Kardiovaskulres system in der urmie cardiovascular system in uremia[J].Der Nephrologe,2020,15(5):275-276.
[9] 邓升华,宫妍,王东梅,等.铜砭刮痧疗法在尿毒症性皮肤瘙痒患者中的应用及效果观察[J].护士进修杂志,2021,36(24):2261-2264.
[10] 王祺.低分子肝素在终末期肾病规律血液透析患者行血液灌流治疗中的安全性及对凝血指标的影响[J].山西医药杂志,2021,50(10):1696-1698.
[11] 骆强,卿山林,尧鹏.血液透析、高通量血液透析及血液透析滤过治疗尿毒症患者的效果及对血清炎症因子、氧化应激指标的影响[J].临床误诊误治,2020,33(4):71-76.
[12] Satarug S,Vesey DA,Nishijo M,Ruangyuttikarn W,Gobe GC.The inverse association of glomerular function and urinary β2-MG excretion and its implications for cadmium health risk assessment[J].Environ Res,2019,12(4):40-47.
[13] 谢萍,张苇,孙萍.血液透析联合rHu EPO对尿毒症贫血患者Hb、Hct水平的影响[J].河北医药,2021,43(2):243-245,249.
[14] Zeng Z,Zheng Q,Chen J,et al.FGF21 mitigates atherosclerosis via inhibition of NLRP3 inflammasome-mediated vascular endothelial cells pyroptosis[J].Experimental Cell Research,2020,393(2):108-116. |
|
|
|
2022, Vol. 28 
